Humanigen Granted U.S. Patent Titled 'METHOD OF INCREASING THE EFFICACY OF CAR-T IMMUNOTHERAPY USING LENZILUMAB'
Portfolio Pulse from Benzinga Newsdesk
Humanigen has been granted a US patent for a method of increasing the efficacy of CAR-T immunotherapy using Lenzilumab. The patent covers the use of Lenzilumab in combination with CAR-T therapy to enhance its effectiveness.
June 13, 2023 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Humanigen's granted patent for increasing CAR-T immunotherapy efficacy using Lenzilumab may lead to increased interest in the company's stock.
The granted patent directly pertains to Humanigen's product, Lenzilumab, and its application in CAR-T immunotherapy. This development may attract investors' attention and lead to increased demand for HGEN stock, driving its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100